persons ) and related services i.e. registration with Food and Drug Administration (FDA), trademark permission, product and packaging design, and brand building etc. to customers who are business operator
transferred on share sale and purchase date from the seller’s connected persons ) and related services i.e. registration with Food and Drug Administration (FDA), trademark permission, product and packaging
. registration with Food and Drug Administration (FDA), trademark permission, product and packaging design, and brand building etc. to customers who are business operator in skin cares and cosmetics. In addition
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
postpaid subscriber continued to grow and now accounts for 19% of total subscriber base, up from 16% in 1Q17. AIS Fibre continued its improving performance amidst competitive environment with revenue growth
ability to grow ARPU with higher data usage. As the fixed-speed low-tier packages were seized during the quarter, the ARPU pressure is expected to gradually ease. Aggressive marketing campaigns around the
center and ICT solution following digitalization trend. 5G mobile subscriber continued to grow strongly supported by new 5G handset launch while 5G package uplifted ARPU by 10-15% 5G mobile subscriber
% QoQ. FY22 guidance maintained. For 9M22, AIS performance was in-line with the guidance. The revenue expects to grow with the seasonality trend in the fourth quarter. A slight decline in EBITDA (-2.4